2025 Q4 -tulosraportti
35 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Irtoamispäivä 27.3.
4,72%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·15 min sitten · MuokattuIf novo gives the same dividend as last year, the dividend is 6% if you buy at a price of 250. It would probably be smarter for novo to buy back shares instead, but they probably don't dare to stop the dividend. Doing both might also be too short-sighted, as one wants to invest in the future. But Novo should rip off the band-aid regarding dividends and just channel the money into buybacks. But novo holds onto the dividend because many investors, including pension funds, funds, especially dividend funds, expect a predictable cash payment. If Novo suddenly removed the dividend, it would be interpreted as a negative signal and some funds would have to sell the stock. But seriously. Even if it is then divested due to the above, novo would just be able to buy back even more shares and no matter what, the price is currently so pathetic that it's almost no longer about the price - but solely about reducing the number of stupid decisions. Some will 100% disagree here.
·12 min sittenThat Novo becoming a good dividend stock is surely much more positive . 6% yield + the chance of the stock rising is surely an optimal stock deal . The stock also becomes more stable then when people and funds hold the stock because of the dividend .
·40 min sittenIt slipped down in after hours and we start the day with a loss. After this, it will be interesting to see what happens. My guess is that it will drift further down towards 220 before Easter.
·19 min sitten · MuokattuOn March 26 and May 6, 2026, the stock will explode when Wall Street and the ridiculous analysts realize that the Wegovy pill is selling extremely well. Massive overperformance: Bank of America originally estimated that Novo only needed 2,000 prescriptions per week to reach their 2026 target. They are now at ten times that. Furthermore, I would also like to mention that patients and doctors care about two things: Weight loss and safety (fewer/milder side effects). Novo is the best pill in both areas, so LLY can well pack it in regarding hyping that one can "take the pill with morning coffee", as in far too many cases there is sour vomit in the coffee, since far too many patients cannot tolerate the pill at all and stop the treatment. The Wegovy pill's supremely higher weight loss and supremely better safety profile are what patients and doctors care about - not which pill is most scalable. Ultimately, it is the patients and doctors who decide. And doctors care a lot about giving their patients the medicine that scores highest on both efficacy and safety. In other words, they don't care who can produce the fastest and cheapest. It's only Wall Street and their "blind tunnel vision" analysts who care about that. The fact is: Novo has the best pill and sales are soaring and exceeding Novo's own expectations. We can therefore also assume that Novo's guidance for the year is set far too conservatively, as the pill sells much more than the approx. 2000 pills per week needed to meet the annual target. And let me also add that most prescriptions are issued to brand new patients, and patients have a strong tendency to remain on the medication they start on. Which pill do you think doctors will prefer to prescribe?! Have a good morning everyone :)
·18 min sittenWell written. If pill sales remain at this level, it alone will cover the negative guidance. The sales figures we are currently seeing for the Wegovy pill are not included in the negative guidance. At the same time, more and more people understand that for weight loss and diabetes, pills are preferable to injections. Novo has a clear lead so far for the inevitable transmission from injection to pill. The share price will probably not make a big leap in the short term, but I believe we will see tendencies of an increase when the prescription numbers for orforglipron are released. With 25% less weight loss for orforglipron versus the Wegovy pill, this also impacts which of these pills insurance companies will reimburse. It will be far more expensive for insurance companies to cover a medicine with a significantly weaker result. Then we must not forget Europe, which is coming in the second half of 2026. Remember that the market in the EU versus the USA has been much worse business as very few get expensive weight loss injections covered. The pills and price per month will make the EU market a new cash cow. 150-300 euro a month opens up for a large volume of self payers compared to self payers for injections today. The Wegovy pill will also get a much larger head start in the EU as EMA does not give prio-vouchers here. It's only a matter of time before the share price skyrockets. In the meantime, just enjoy a beer in the sun. It
·41 min sittenAfter a brief dip yesterday, with a new buying opportunity, Novo continues its upward journey today. We start in the green and close in the green. And here we're not just talking about Tuborg, or rather we are, but also that the share is rising. Steadily forward with a price of 460 at the end of 2926.·34 min sitten · MuokattuIt starts red and closes red. Another day where Novo is trickling down. And make sure to get a couple of cold beers, because you'll need something to calm your nerves with.
1 t sitten1 t sitten
·1 t sittenYou’ve been rickrolled. Never gonna give you up! Make it a habit to describe what is behind a link. I think many of us don't bother to follow an unknown link to something irrelevant.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
35 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Irtoamispäivä 27.3.
4,72%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·15 min sitten · MuokattuIf novo gives the same dividend as last year, the dividend is 6% if you buy at a price of 250. It would probably be smarter for novo to buy back shares instead, but they probably don't dare to stop the dividend. Doing both might also be too short-sighted, as one wants to invest in the future. But Novo should rip off the band-aid regarding dividends and just channel the money into buybacks. But novo holds onto the dividend because many investors, including pension funds, funds, especially dividend funds, expect a predictable cash payment. If Novo suddenly removed the dividend, it would be interpreted as a negative signal and some funds would have to sell the stock. But seriously. Even if it is then divested due to the above, novo would just be able to buy back even more shares and no matter what, the price is currently so pathetic that it's almost no longer about the price - but solely about reducing the number of stupid decisions. Some will 100% disagree here.·12 min sittenThat Novo becoming a good dividend stock is surely much more positive . 6% yield + the chance of the stock rising is surely an optimal stock deal . The stock also becomes more stable then when people and funds hold the stock because of the dividend .
- ·40 min sittenIt slipped down in after hours and we start the day with a loss. After this, it will be interesting to see what happens. My guess is that it will drift further down towards 220 before Easter.
- ·19 min sitten · MuokattuOn March 26 and May 6, 2026, the stock will explode when Wall Street and the ridiculous analysts realize that the Wegovy pill is selling extremely well. Massive overperformance: Bank of America originally estimated that Novo only needed 2,000 prescriptions per week to reach their 2026 target. They are now at ten times that. Furthermore, I would also like to mention that patients and doctors care about two things: Weight loss and safety (fewer/milder side effects). Novo is the best pill in both areas, so LLY can well pack it in regarding hyping that one can "take the pill with morning coffee", as in far too many cases there is sour vomit in the coffee, since far too many patients cannot tolerate the pill at all and stop the treatment. The Wegovy pill's supremely higher weight loss and supremely better safety profile are what patients and doctors care about - not which pill is most scalable. Ultimately, it is the patients and doctors who decide. And doctors care a lot about giving their patients the medicine that scores highest on both efficacy and safety. In other words, they don't care who can produce the fastest and cheapest. It's only Wall Street and their "blind tunnel vision" analysts who care about that. The fact is: Novo has the best pill and sales are soaring and exceeding Novo's own expectations. We can therefore also assume that Novo's guidance for the year is set far too conservatively, as the pill sells much more than the approx. 2000 pills per week needed to meet the annual target. And let me also add that most prescriptions are issued to brand new patients, and patients have a strong tendency to remain on the medication they start on. Which pill do you think doctors will prefer to prescribe?! Have a good morning everyone :)·18 min sittenWell written. If pill sales remain at this level, it alone will cover the negative guidance. The sales figures we are currently seeing for the Wegovy pill are not included in the negative guidance. At the same time, more and more people understand that for weight loss and diabetes, pills are preferable to injections. Novo has a clear lead so far for the inevitable transmission from injection to pill. The share price will probably not make a big leap in the short term, but I believe we will see tendencies of an increase when the prescription numbers for orforglipron are released. With 25% less weight loss for orforglipron versus the Wegovy pill, this also impacts which of these pills insurance companies will reimburse. It will be far more expensive for insurance companies to cover a medicine with a significantly weaker result. Then we must not forget Europe, which is coming in the second half of 2026. Remember that the market in the EU versus the USA has been much worse business as very few get expensive weight loss injections covered. The pills and price per month will make the EU market a new cash cow. 150-300 euro a month opens up for a large volume of self payers compared to self payers for injections today. The Wegovy pill will also get a much larger head start in the EU as EMA does not give prio-vouchers here. It's only a matter of time before the share price skyrockets. In the meantime, just enjoy a beer in the sun. It
- ·41 min sittenAfter a brief dip yesterday, with a new buying opportunity, Novo continues its upward journey today. We start in the green and close in the green. And here we're not just talking about Tuborg, or rather we are, but also that the share is rising. Steadily forward with a price of 460 at the end of 2926.·34 min sitten · MuokattuIt starts red and closes red. Another day where Novo is trickling down. And make sure to get a couple of cold beers, because you'll need something to calm your nerves with.
- 1 t sitten1 t sitten·1 t sittenYou’ve been rickrolled. Never gonna give you up! Make it a habit to describe what is behind a link. I think many of us don't bother to follow an unknown link to something irrelevant.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
2025 Q4 -tulosraportti
35 päivää sitten
‧1 t 12 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
7,95 DKK/osake
Irtoamispäivä 27.3.
4,72%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·15 min sitten · MuokattuIf novo gives the same dividend as last year, the dividend is 6% if you buy at a price of 250. It would probably be smarter for novo to buy back shares instead, but they probably don't dare to stop the dividend. Doing both might also be too short-sighted, as one wants to invest in the future. But Novo should rip off the band-aid regarding dividends and just channel the money into buybacks. But novo holds onto the dividend because many investors, including pension funds, funds, especially dividend funds, expect a predictable cash payment. If Novo suddenly removed the dividend, it would be interpreted as a negative signal and some funds would have to sell the stock. But seriously. Even if it is then divested due to the above, novo would just be able to buy back even more shares and no matter what, the price is currently so pathetic that it's almost no longer about the price - but solely about reducing the number of stupid decisions. Some will 100% disagree here.·12 min sittenThat Novo becoming a good dividend stock is surely much more positive . 6% yield + the chance of the stock rising is surely an optimal stock deal . The stock also becomes more stable then when people and funds hold the stock because of the dividend .
- ·40 min sittenIt slipped down in after hours and we start the day with a loss. After this, it will be interesting to see what happens. My guess is that it will drift further down towards 220 before Easter.
- ·19 min sitten · MuokattuOn March 26 and May 6, 2026, the stock will explode when Wall Street and the ridiculous analysts realize that the Wegovy pill is selling extremely well. Massive overperformance: Bank of America originally estimated that Novo only needed 2,000 prescriptions per week to reach their 2026 target. They are now at ten times that. Furthermore, I would also like to mention that patients and doctors care about two things: Weight loss and safety (fewer/milder side effects). Novo is the best pill in both areas, so LLY can well pack it in regarding hyping that one can "take the pill with morning coffee", as in far too many cases there is sour vomit in the coffee, since far too many patients cannot tolerate the pill at all and stop the treatment. The Wegovy pill's supremely higher weight loss and supremely better safety profile are what patients and doctors care about - not which pill is most scalable. Ultimately, it is the patients and doctors who decide. And doctors care a lot about giving their patients the medicine that scores highest on both efficacy and safety. In other words, they don't care who can produce the fastest and cheapest. It's only Wall Street and their "blind tunnel vision" analysts who care about that. The fact is: Novo has the best pill and sales are soaring and exceeding Novo's own expectations. We can therefore also assume that Novo's guidance for the year is set far too conservatively, as the pill sells much more than the approx. 2000 pills per week needed to meet the annual target. And let me also add that most prescriptions are issued to brand new patients, and patients have a strong tendency to remain on the medication they start on. Which pill do you think doctors will prefer to prescribe?! Have a good morning everyone :)·18 min sittenWell written. If pill sales remain at this level, it alone will cover the negative guidance. The sales figures we are currently seeing for the Wegovy pill are not included in the negative guidance. At the same time, more and more people understand that for weight loss and diabetes, pills are preferable to injections. Novo has a clear lead so far for the inevitable transmission from injection to pill. The share price will probably not make a big leap in the short term, but I believe we will see tendencies of an increase when the prescription numbers for orforglipron are released. With 25% less weight loss for orforglipron versus the Wegovy pill, this also impacts which of these pills insurance companies will reimburse. It will be far more expensive for insurance companies to cover a medicine with a significantly weaker result. Then we must not forget Europe, which is coming in the second half of 2026. Remember that the market in the EU versus the USA has been much worse business as very few get expensive weight loss injections covered. The pills and price per month will make the EU market a new cash cow. 150-300 euro a month opens up for a large volume of self payers compared to self payers for injections today. The Wegovy pill will also get a much larger head start in the EU as EMA does not give prio-vouchers here. It's only a matter of time before the share price skyrockets. In the meantime, just enjoy a beer in the sun. It
- ·41 min sittenAfter a brief dip yesterday, with a new buying opportunity, Novo continues its upward journey today. We start in the green and close in the green. And here we're not just talking about Tuborg, or rather we are, but also that the share is rising. Steadily forward with a price of 460 at the end of 2926.·34 min sitten · MuokattuIt starts red and closes red. Another day where Novo is trickling down. And make sure to get a couple of cold beers, because you'll need something to calm your nerves with.
- 1 t sitten1 t sitten·1 t sittenYou’ve been rickrolled. Never gonna give you up! Make it a habit to describe what is behind a link. I think many of us don't bother to follow an unknown link to something irrelevant.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt